Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation?
- 1 January 2007
- journal article
- Published by Springer Science and Business Media LLC in Pediatric Nephrology
- Vol. 22 (1), 158-160
- https://doi.org/10.1007/s00467-006-0260-x
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Resolution of Recurrent Focal Segmental Glomerulosclerosis Proteinuria after Rituximab TreatmentNew England Journal of Medicine, 2006
- B lymphocyte depletion therapy in children with refractory systemic lupus erythematosusArthritis & Rheumatism, 2005
- B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patientsRheumatology, 2005
- Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndromePediatric Nephrology, 2005
- Anti B cell therapy (rituximab) in the treatment of autoimmune diseasesCurrent Opinion in Pharmacology, 2004
- Humanized anti‐CD20 monoclonal antibody (Rituximab) treatment for post‐transplant lymphoproliferative disorder*Clinical Transplantation, 2003
- B cell depletion in autoimmune diseaseArthritis Research & Therapy, 2003
- Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytesRheumatology, 2001
- Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma.2000
- Recurrent nephrotic syndrome after transplantation: Early treatment with plasmaphaeresis and cyclophosphamidePediatric Nephrology, 1993